Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Apoptotic anti-ige antibodies

An antibody and apoptosis technology, applied in the direction of antibodies, drug combinations, anti-infective drugs, etc., can solve problems such as B cell apoptosis

Inactive Publication Date: 2010-03-24
GENENTECH INC
View PDF115 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Surprisingly, Applicants have discovered that targeting the M1' segment of IgE with an anti-IgE antibody results in the induction of apoptosis in B cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Apoptotic anti-ige antibodies
  • Apoptotic anti-ige antibodies
  • Apoptotic anti-ige antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0422] Example 1: Isolation of primate IgE

[0423] Human IgE was cloned from the human IgE myeloma cell line U266 (ATCC, Manassas, VA, TIB #196). Rhesus and macaque IgE sequences were determined by cloning and sequencing of IgE from cDNA derived from rhesus and macaque peripheral blood mononuclear cells (PBMCs) that had been stimulated to generate IgE-switched cells (PBMCs). Forward and reverse primers (shown below) were designed from human IgE sequences. The upstream forward primer was designed just upstream of the CH2 domain. The reverse primer was designed at the end of the transmembrane domain. Rhesus and macaque PBMCs were obtained from California National Primate Research Center, Davis, CA. Will 5x10 6 Each PBMC was cultured with IL-4 (100 ng / ml) and CD40L (3 μg / ml) (R&D Systems, Minneapolis, MN, #204-IL and #617-CL, respectively) for 4 days. Cells were then harvested, RNA was prepared (RNeasy Mini Kit, #74106, Qiagen, Valencia, CA), and cDNA was prepared using the...

Embodiment 2

[0429] Example 2: Isolation of Anti-IgE / M1' Antibody

[0430] Generation of CH3-CH4-M1' / Fc fusion protein

[0431] The human IgE CH3-CH4-M1' / Fc fusion protein was generated by PCR amplifying the human IgE CH3-CH4-M1' domain from cDNA prepared from U266 cells (ATTC Manassas, VA, TIB #196), plus An additional 15 amino acids just downstream of the M1' domain. RNA was prepared from U266 cells (RNeasyMini Kit, #74106, Qiagen, Valencia, CA) and cDNA was prepared using the BD SprintPowerscript Oligo dT Priming Kit (BD Biosciences, San Jose, CA, #639558). RT-PCR was performed and PCR products were cloned by TOPO-TA cloning (Invitrogen, Carlsbad, CA, #45-0641). The N-terminal signal sequence was added by PCR mutagenesis for expression in mammalian cells, and the signal sequence +CH3+CH4+M1'+15 amino acids were cloned into an expression vector (pRK huIgG1 Fc; Genentech) to generate C-terminal fusion of IgG1 Fc region. The sequence of the final protein (including signal sequence and ...

Embodiment 2A

[0568] Example 2A: Humanization of Anti-IgE / M1' Antibodies

[0569] This example describes the humanization of murine anti-IgE / M1' antibodies 26A11, 7A6 and 47H4.

[0570] Materials and methods

[0571] The M1' domain of membrane-bound human IgE was expressed as an Fc fusion in CHO cells and purified by conventional means. Hybridomas expressing antibodies 26A11, 7A6 and 47H4 were obtained by immunizing mice with recombinant M1'-Fc fusion protein and identified by ELISA using M1'-Fc-coated plates. Functional antibodies are identified by their ability to bind M1'-expressing cells and promote apoptosis.

[0572] Cloning of murine 26A11, 7A6 and 47H4 variable domains - Total RNA was extracted from hybridoma cells producing 26A11, 7A6 or 47H4 using standard methods. The light chain variable domain (VL) and heavy chain variable domain (VH) were amplified using RT-PCR with degenerate primers for the heavy and light chains. The forward primers are specific for the N-terminal ami...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.

Description

[0001] related application [0002] This application claims priority under 35 U.S.C. §119(e) to U.S.S.N. 60 / 896,339, filed March 22, 2007. field of invention [0003] The present invention relates to apoptotic anti-IgE antibodies, nucleic acids encoding them, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. Background of the invention [0004] Allergy / allergy refers to certain diseases in which the immune response to environmental antigens causes tissue inflammation and organ dysfunction. The clinical features of each allergic disease reflect an immunologically induced inflammatory response in the organ or tissue involved. These characteristics are generally independent of the chemical or physical properties of the antigen. The diversity of allergic responses results from the involvement of different immunological effector pathways, each generating a unique pattern of inflammation. [0005] Allergies are common throughout the wor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/42A61P37/06
CPCC07K16/4291A01K2267/0387A01K2227/105A01K67/0278C07K2317/21A01K2217/072C07K2316/95A61K2039/505C07K2317/41C07K2317/73C07K2317/24A61P1/04A61P11/00A61P11/02A61P11/06A61P13/10A61P17/00A61P17/04A61P19/00A61P31/10A61P33/00A61P35/00A61P37/00A61P37/02A61P37/06A61P37/08A61P43/00C07K16/42A61K39/395
Inventor 劳伦·吴梅塞德丝·巴拉兹汉斯·布赖特比尔安德鲁·陈伊冯娜·陈阿南·丘恩撒拉佩马克·丹尼斯特伦斯·王
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com